Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler

March 6, 2023 updated by: Johanne Severinsen, Danish Headache Center

Assessment of Raised Intracranial Pressure in Patients With Idiopathic Intracranial Hypertension by Optic Nerve Sheath Diameter and Transcranial Doppler Measurements

Idiopathic Intracranial Hypertension (IIH) is a rare disease, primarily affecting overweight females of child-bearing age. Patients suffer from increased intracranial pressure (ICP), typically resulting in headaches, visual disturbances and bilateral papilledema, pulsatile tinnitus and cognitive deficits. The disease is difficult to diagnose, treat and monitor. The only current method of measuring the ICP in day-to-day clinical practice is by lumbar puncture. This procedure is invasive, and often painful for the patient. There is an unmet need of methods that can reliable measure or estimate ICP in a non-invasive manner. Ultrasound is one such potential method, and the aim of this study is to investigate the use of ocular ultrasound and transcranial doppler to measure or estimate ICP.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This study is a prospective cohort study. Investigators plan to include 50 patients in whom the IIH-diagnosis is suspected. Patients are referred from general practitioners, neurologists or ophthalmologists to the Danish Headache Center or admitted to the Neurology ward when the IIH diagnosis is suspected.

As part of an established routine clinical work-up to establish the diagnosis of IIH, all patients will undergo (according to the Friedman criteria) the following examinations:

A)

  1. An interview (history taking) and clinical examination
  2. Routine laboratory tests (blood tests)
  3. Ophthalmological examination
  4. Lumbar puncture with measurement of the ICP
  5. Magnetic resonance imaging (MRI) of the brain

Additionally the following investigations will be performed at baseline (before and after lumbar puncture):

B) Transorbital sonography (TOS) C) Transcranial Doppler When the patient is seen at the clinic for their regular follow-up visits the same measurements will be done.

A control group of healthy participants (NR=25) will be included in whom TOS (B) and TCD (C) will be performed in order to compare the values between the patient group (IIH) and control group. Controls will be included to match the patients according to BMI, age and gender.

All ultrasound images- and films will be saved, and evaluated by a blinded investigator.

Study Type

Interventional

Enrollment (Actual)

78

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Region Hovedstaden
      • Glostrup, Region Hovedstaden, Denmark, 2600
        • Danish Headache Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

PATIENT GROUP (ARM 1):

Inclusion Criteria:

  • Age 18-65
  • Patients in whom the IIH diagnosis is suspected/or confirmed
  • The diagnosis of migraine with or without aura or tension-type headache is allowed as a comorbid headache type.
  • Participants must read and understand the Danish language, or have an official interpreter present to be able to understand the work-up and sign the participation consent for the study

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Patients who do not need a diagnostic lumbar puncture at the time of evaluation
  • Patients treated with acetazolamide, topiramate or furosemide for IIH or suspected IIH before inclusion in the study (baseline)
  • Any other primary or secondary headache diagnosis than migraine with or without aura or tension type headache as a comorbid disorder
  • Patients in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases
  • Participants with secondary causes of raised intracranial pressure, or patients that have been treated for such (e.g. brain tumor, hydrocephalus, stroke or severe head injury)
  • Participants with known atherosclerotic disease or known heart disease

CONTROL GROUP (ARM 2):

Inclusion criteria:

  • Age 18-65
  • Healthy persons who do not suffer from any form of primary headache except infrequent tension-type headache
  • Participants must read and understand the Danish language or have an official interpreter present to be able to sign the participation consent for the study.

Exclusion criteria:

  • Pregnant or breastfeeding females
  • Participants in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients suspected of IIH at baseline

Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.

Healthy controls will be recruited to match the patients.

TOS: Transorbital sonography TCD: Transcranial Doppler

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between opening pressure and ONSD
Time Frame: 1 year
Optic nerve sheath diameter (ONSD) potential correlation with opening pressure.
1 year
Correlaton between opening pressure and ONSD/ETD ratio
Time Frame: 1 year
ONSD/ETD (external transverse diameter) ratio and potential correlation with opening pressure.
1 year
Comparison of ONSD in IIH and healthy controls
Time Frame: 1 year
Comparison of ONSD in patients with elevated ICP (IIH) and healthy controls, age- sex and BMI matched.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optic disc elevation
Time Frame: 1 year
Optic disc elevation measured by ultrasound in IIH compared with healthy controls
1 year
ONSD diameter on MR c in patients with IIH
Time Frame: 1 year
ONSD and correlation with ONSD on orbital MRI.
1 year
Changes in the optic nerve (ONSD)
Time Frame: 1 month
Changes in ONSD after 1 month
1 month
Changes in the optic nerve (ONSD)
Time Frame: 6 months
Changes in ONSD after 6 months
6 months
Changes in the optic nerve (ODE)
Time Frame: 1 month
Changes in ODE (optic disc elevation) after 1 month
1 month
Changes in the optic nerve (ODE)
Time Frame: 6 months
Changes in ODE(optic disc elevation) after 6 months
6 months
TCD (PI - pulsatility index) in patients with IIH
Time Frame: 2 years
Evaluation of pulsatility index for major intracranial arteries (PI) using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.
2 years
TCD (MBFV - mean blood flow velocity) in patients with IIH
Time Frame: 2 years
Evaluation of mean blood flow velocity (MBFV) for major intracranial arteries using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.
2 years
TCD (RI - resistance index) in patients with IIH
Time Frame: 2 years
Evaluation of resistance index (RI) for major intracranial arteries using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.
2 years
Neuro-ophthalmological evaluation of papilledema versus ultrasound evaluation of the optic nerve
Time Frame: 2 years
Papilledema and the optic nerve is usually evaluated by neuro-ophthalmologists in patients with IIH. Investigators will compare this evaluation with the assessment made by TOS ultrasound.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rigmor Jensen, Dr.med., Danish Headache Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Actual)

February 1, 2023

Study Completion (Actual)

February 1, 2023

Study Registration Dates

First Submitted

March 12, 2020

First Submitted That Met QC Criteria

March 18, 2020

First Posted (Actual)

March 19, 2020

Study Record Updates

Last Update Posted (Estimate)

March 7, 2023

Last Update Submitted That Met QC Criteria

March 6, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Intracranial Hypertension

Clinical Trials on TOS and TCD

Subscribe